MULPLETA (lusutrombopag tablets) for oral use. Initial U.S. Approval: 2018

Category: .

MULPLETA (lusutrombopag tablets) for oral use. Initial U.S. Approval: 2018

INDICATIONS AND USAGE
MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
DOSAGE FORMS & STRENGTHS
Tablet: 3 mg
Manufactured By: Shionogi Inc.
Prescribing Information URL: Click Here

Access to MULPLETA (lusutrombopag tablets) for oral use: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi. It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.
It was approved for medical use in the European Union in February 2019.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.